165108-07-6

Basic information

• Product Name: Avermectin A1a, 25-cyclohexyl-4-O-de(2,6-dideoxy-3-O-methyl-.alpha.-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-
• Synonyms: Avermectin A1a, 25-cyclohexyl-4-O-de(2,6-dideoxy-3-O-methyl-.alpha.-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-;25-Cyclohexyl-25-de(1-methylpropyl)-5-deoxy-22 23-dihydro-5-(hydroxyimino)-avermectin B1 monosaccharide;Avermectin A1A, 25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-A-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-;Selamectin [usan:inn];Uk-124,114;Unii-A2669owx9n;25-Cyclohexyl-4'-O-de(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)avermectin A1a;SelaMeerin
• CAS NO: 165108-07-6
• Molecular Formula: C43H63NO11
• Molecular Weight: 769.96
• Mol File: 165108-07-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 917 °C at 760 mmHg
• Flash Point: 508.4 °C
• Appearance: /
• Density: 1.35
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.618
• PKA: 10.18±0.70(Predicted)
• CAS DataBase Reference: Avermectin A1a, 25-cyclohexyl-4-O-de(2,6-dideoxy-3-O-methyl-.alpha.-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-(CAS DataBase Reference)
• NIST Chemistry Reference: Avermectin A1a, 25-cyclohexyl-4-O-de(2,6-dideoxy-3-O-methyl-.alpha.-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-(165108-07-6)
• EPA Substance Registry System: Avermectin A1a, 25-cyclohexyl-4-O-de(2,6-dideoxy-3-O-methyl-.alpha.-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-(165108-07-6)

Safety Data

• Hazardous Substances Data: 165108-07-6(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 165108-07-6 differently. You can refer to the following data:
1. Antiparasitic (veterinary).
2. Selamectin is used in the preparation of new antiparasitic agents and insecticides.

InChI:InChI=1/C43H63NO11/c1-24-11-10-14-30-23-50-40-36(44-48)27(4)19-33(43(30,40)47)41(46)52-32-20-31(16-15-25(2)38(24)53-35-21-34(49-6)37(45)28(5)51-35)54-42(22-32)18-17-26(3)39(55-42)29-12-8-7-9-13-29/h10-11,14-15,19,24,26,28-29,31-35,37-40,45,47-48H,7-9,12-13,16-18,20-23H2,1-6H3/b11-10+,25-15+,30-14+,44-36-/t24-,26-,28-,31+,32-,33-,34-,35?,37?,38-,39-,40+,42+,43+/m0/s1

Upstream product

• 142680-85-1 C₅₀H₇₆O₁₄ 
• 142680-85-1 doramectin 
• 117704-25-3 doramectin 

Relevant articles and documents

New Selamectin Intermediates, Preparation Method Thereof And Preparation Method For Selamectin Using The Same

The present invention relates to a novel intermediate of selamectin which is an antiparasitic drug, a manufacturing method thereof, and an improved method for manufacturing selamectin using the same. More particularly, the present invention relates to: the novel intermediate produced by a four-step synthesis process of a deglycosylation reaction, a hydrogenation reaction, an oxidation reaction, and an oximation reaction; and the improved method of selamectin using the same. The novel intermediate of selamectin according to the present invention has thermal and chemical stability and by using the novel method for manufacturing selamectin of the present invention, it is possible to manufacture selamectin having a higher synthesis yield and purity compared to existing technology.COPYRIGHT KIPO 2019

Preparation method of selamectin

The invention provides an improved preparation technology of selamectin. The improved preparation technology comprises the following steps of (1) in the presence of a Wilson catalyst, reducing the selamectin DL by hydrogen, so as to obtain an intermediate SL1; (2) desugaring the intermediate SL1 obtained in step (1) by an organic solvent hydrochloric acid solution (by dissolving hydrochloric acid gas into an organic solvent), so as to obtain an intermediate SL2; (3) oxidizing the intermediate SL2 obtained in step (2) by manganese dioxide, so as to obtain an intermediate SL3; (4) oximating the intermediate SL3 obtained in step (3) by hydroxylamine hydrochloride, so as to obtain selamectin SL; (5) recrystallizing the crude product of selamectin SL obtained in step (4) by methylbenzene, acetone and methanol, so as to obtain the purified selamectin SL.